MoneyWorks4Me

Hikal - Quaterly Results

12 Nov 2024 Evaluate
With no major difference for the quarter endedSeptember 2024 , the total revenue stood at Rs. 4529.00  millions.An average growth of 44.80% was recorded for the quarter ended September 2024 to Rs. 181.00  millions from Rs. 125.00 millions.Operating Profit saw a handsome growth to 751.00 millions from 585.00 millions in the quarter ended September 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 4529.00 4349.00 4.14 8597.00 8229.00 4.47 17846.00 20230.30 -11.79
Other Income 4.00 10.00 -60.00 9.00 19.00 -52.63 24.50 54.10 -54.71
PBIDT 751.00 585.00 28.38 1337.00 1097.00 21.88 2693.90 2624.70 2.64
Interest 188.00 131.00 43.51 386.00 269.00 43.49 563.70 481.00 17.19
PBDT 563.00 454.00 24.01 951.00 828.00 14.86 2130.20 2143.70 -0.63
Depreciation 317.00 286.00 10.84 635.00 563.00 12.79 1176.10 1090.10 7.89
PBT 246.00 168.00 46.43 316.00 265.00 19.25 954.10 1053.60 -9.44
TAX 65.00 43.00 51.16 83.00 71.00 16.90 259.00 269.80 -4.00
Deferred Tax -2.00 -2.00 0.00 1.00 -1.00 -200.00 -24.70 -35.00 -29.43
PAT 181.00 125.00 44.80 233.00 194.00 20.10 695.10 783.80 -11.32
Equity 247.00 247.00 0.00 247.00 247.00 0.00 246.60 246.60 0.00
PBIDTM(%) 16.58 13.45 23.27 15.55 13.33 16.66 15.10 12.97 16.35
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..